European CHMP recommends approval of two bevacizumab biosmilars (Abevmy and Lextemy)

Studies found that both these brands were highly similar with comparable quality, safety and efficacy to the reference product Avastin. They will be licensed for the range of indications as per Avastin.

European Medicines Agency